Eli Lilly and Co. announced Monday that it is buying Boston-based Scorpion Therapeutics and its targeted breast cancer ...

Eli Lilly and Company (LLY) on Monday said it has agreed to buy Scorpion Therapeutics' experimental cancer therapy PI3Ka inhibitor ...

Eli Lilly’s chief scientific officer said the company purchased a cancer drug from the startup Scorpion Therapeutics because ...

Eli Lilly said it would acquire a cancer program from Scorpion Therapeutics in a deal worth up to $2.5 billion, as it ...

The pharma will spend up to $2.5 billion to acquire an experimental PI3K inhibitor from Scorpion, which will spin out a new ...

Eli Lilly said on Monday it would buy cancer therapy developer Scorpion Therapeutics for up to $2.5 billion in cash. Lilly ...

Eli Lilly said on Monday it plans to buy Scorpion Therapeutics' experimental cancer therapy for up to $2.5 billion in cash to ...

Eli Lilly plans to acquire Scorpion's PI3Kα program for $2.5 billion, reinvesting Mounjaro and Zepbound profits to expand its precision medicines pipeline.

Eli Lilly (LLY) and Scorpion Therapeutics announced a definitive agreement for Lilly to acquire Scorpion’s PI3Kalpha ...

Eli Lilly is reenergizing its attempt to challenge Novartis and Roche for a breast cancer market, kicking off the J.P. Morgan ...

Eli Lilly agreed to acquire Scorpion Therapeutics’ breast cancer treatment program for up to $2.5 billion in cash.

Eli Lilly in talks to acquire cancer biotech Scorpion Therapeutics for $2.5 billion, with potential milestone payments.